Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 32Cisplatin 23Cetuximab 14Carboplatin 13Magnetic Resonance Spectroscopy 12Specimen Handling 10Radiotherapy, Intensity-Modulated 10Paclitaxel 9Nivolumab 9Docetaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Radiotherapy 5Biopsy 5dostarlimab 4atezolizumab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Taxes 3Radiation 3Fulvestrant 3Fluorouracil 3budigalimab 2amivantamab 2abemaciclib 2Radiotherapy, Image-Guided 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Imlunestrant × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡